Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2013-02-08 | Reverse | 1:5 |
| 2012-03-16 | Reverse | 1:8 |
| 2012-02-24 | Reverse | 1:8 |
| 2007-09-28 | Reverse | 231:500 |
Harrow Health, Inc. is an ophthalmology-focused healthcare company owning ImprimisRx, DEXYCU, and stakes in clinical-stage pharma firms, developing and commercializing ocular therapeutics and related products.
VEVYE, launched in the U.S. in January 2024, is the first patented, non-preserved, twice-daily cyclosporine eye drop for dry eye disease, promoted with a money-back guarantee and patient access programs.
Harrow Health, Inc. announced its third-quarter 2025 financial results on November 10, 2025, reporting a 45% increase in total revenues to $71.6 million compared to the same period in the previous year. The company also reported a GAAP net income of $1.0 million and an earnings per share (EPS) of $0.33, significantly surpassing analyst expectations. This strong financial performance, coupled with strategic announcements including the impending acquisition of Melt Pharmaceuticals and expanded payer coverage for its key drug VEVYE, led to a notable positive investor response.
In a major strategic shift, Harrow Health launched 'Harrow Access for All' (HAFA), a comprehensive program designed to make its full range of ophthalmic medications more affordable and accessible for patients. This initiative builds on the success of a similar program for its drug VEVYE and aims to cap out-of-pocket costs for eligible patients, thereby streamlining the prescribing process for physicians and improving patient access to treatments.
Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $63.00 target price on the stock. BTIG Research's price objective indicates a potential upside of 106.19% from the company's current price. Several
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and American Academy of Ophthalmology's (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were traded during trading, a decline of 75% from the average daily volume of 699,208 shares. The stock had previously closed at $33.07. Wall Street
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 72.8% of Harrow shares are
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 BLCO | $17.32 | COMPARE |
 KOD | $92.18 | COMPARE |
 TARS | $74.22 | COMPARE |
 ALVO | $6.08 | COMPARE |
 BLFS | $38.61 | COMPARE |
 TRVI | $13.23 | COMPARE |
 OCUL | $7.46 | COMPARE |
 KMTS | $27.34 | COMPARE |
